Pfizer Will Examine Genizon Genomic Data For Biomarkers
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm will use the collaboration as a discovery platform for biomarkers for Alzheimer's disease, ADHD and endometriosis.
You may also be interested in...
Alzheimer’s Drug Development Comparable To Cancer 50 Years Ago, Says Targacept CEO
Biomarkers and diagnostic tools must be developed to allow drug manufacturers to target Alzheimer’s disease modification, BioInvestor Forum panelists say.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.